Navalign LLC’s GSK GSK Stock Holding History

Navalign LLC’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-80	Closed	-$3.92K	–	266
2025 Q4	$3.92K	Buy	+80	New	+$3.73K	﹤0.01%	392

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Navalign LLC's GSK Position: Q1 2026 in Review

Navalign LLC sold out of GSK (GSK) in Q1 2026, closing a stake of 80 shares — an estimated $3.92K sold.

Navalign LLC first reported a position in GSK in Q4 2025 and held it in 1 quarter. The position peaked at $3.92K in Q4 2025. 1,034 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Navalign LLC reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
Navalign LLC sold 80 GSK shares in Q1 2026, an estimated $3.92K.
Navalign LLC first reported a position in GSK in Q4 2025 and held it in 1 quarter.
Navalign LLC's GSK position peaked at $3.92K in Q4 2025.
1,034 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Navalign LLC's 13F filing for Q1 2026, filed 29 Apr 2026.